to support an emergency use authorization request under section 564 or an application under section 351(a) of the Public Health Service Act. (F) Such other activities as the Secretary determines necessary or appropriate. (3) Rule of construction Nothing in this subsection shall be construed to alter the authority of the Secretary to license, approve, clear, or authorize countermeasures, including biological products, pursuant to section 351 of the Public Health Service Act or section 505 or 564 of this Act, including standards of evidence and applicable conditions for licensure, approval, clearance, or authorization. . (b) Authorization of appropriations To carry out subsection (j) of section 565 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360bbb–4 ), as added by subsection (a), there are authorized to be appropriated such sums as may be necessary for each of fiscal years 2024 through 2028. III Addressing the needs of all individuals 301. Transition of certain countermeasures between compensation programs (a) Treatment of certain ineligible requests related to COVID–19 countermeasures (1) Requests initially submitted under CICP (A) In general In the case of a request for compensation submitted under section 319F–4 of the Public Health Service Act ( 42 U.S.C. 247d–6e ) for an injury or death related to a COVID–19 vaccine that the Secretary determines to be ineligible pursuant to subparagraph (B) of such section 319F–4(b)(4), as added by subsection (b)(1), the Secretary shall, not later than 30 days after such determination, notify the individual submitting the request of such determination. (B) Submission of petition An individual who receives a notification described in subparagraph (A) shall be eligible to submit a petition to the United States Court of Federal Claims under section 2111 of the Public Health Service Act ( 42 U.S.C. 300aa–11 ) with respect to the same vaccine administration claimed in the request submitted under section 319F–4 of such Act ( 42 U.S.C. 247d–6e ), provided that such